Elan ‘to double’ Tysabri share

ELAN is hoping to double its share of the multiple sclerosis treatment market, — through its headline drug, Tysabri — to 20%, within the next four years.

Chief executive Kelly Martin yesterday said that target is “very appropriate,” given Elan already has a near 12% share of the market.

It is hoped that Elan’s pending test programme for patients to see if they have the so-called JC Virus — the main cause of PML, the rare and potentially fatal brain disease that is sometimes a side effect of Tysabri — will significantly reduce the risk of users contracting PML.